Lipoprotein(a) and cardiovascular disease in diabetic patients

Qibin Qi, Lu Qi

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Lipoprotein(a) (Lp[a]) is a LDL-like particle consisting of an ApoA moiety linked to one molecule of ApoB100. Recent data from large-scale prospective studies and genetic association studies provide highly suggestive evidence for a potentially causal role of Lp(a) in affecting risk of cardiovascular disease (CVD) in general populations. Patients with Type 2 diabetes display clustered metabolic abnormalities and elevated risk of CVD. Lower plasma Lp(a) levels were observed in diabetic patients in several recent studies. Epidemiology studies of Lp(a) and CVD risk in diabetic patients generated inconsistent results. We recently found that Lp(a)-related genetic markers did not predict CVD in two diabetic cohorts. The current data suggest that Lp(a) may differentially affect cardiovascular risk in diabetic patients and in the general population. More prospective studies, Mendelian randomization analysis and functional studies are needed to clarify the causal relationship of Lp(a) and CVD in diabetic patients.

Original languageEnglish (US)
Pages (from-to)397-407
Number of pages11
JournalClinical Lipidology
Volume7
Issue number4
DOIs
StatePublished - Aug 2012
Externally publishedYes

Fingerprint

Lipoprotein(a)
Cardiovascular Diseases
Mendelian Randomization Analysis
Prospective Studies
Apolipoproteins A
Genetic Association Studies
Genetic Markers
Type 2 Diabetes Mellitus
Population
Epidemiology

Keywords

  • cardiovascular disease
  • diabetes
  • lipoprotein(a)
  • Mendelian randomization
  • prospective studies

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Lipoprotein(a) and cardiovascular disease in diabetic patients. / Qi, Qibin; Qi, Lu.

In: Clinical Lipidology, Vol. 7, No. 4, 08.2012, p. 397-407.

Research output: Contribution to journalArticle

@article{e75ff098c37b430fb85c0fd9214bfaf6,
title = "Lipoprotein(a) and cardiovascular disease in diabetic patients",
abstract = "Lipoprotein(a) (Lp[a]) is a LDL-like particle consisting of an ApoA moiety linked to one molecule of ApoB100. Recent data from large-scale prospective studies and genetic association studies provide highly suggestive evidence for a potentially causal role of Lp(a) in affecting risk of cardiovascular disease (CVD) in general populations. Patients with Type 2 diabetes display clustered metabolic abnormalities and elevated risk of CVD. Lower plasma Lp(a) levels were observed in diabetic patients in several recent studies. Epidemiology studies of Lp(a) and CVD risk in diabetic patients generated inconsistent results. We recently found that Lp(a)-related genetic markers did not predict CVD in two diabetic cohorts. The current data suggest that Lp(a) may differentially affect cardiovascular risk in diabetic patients and in the general population. More prospective studies, Mendelian randomization analysis and functional studies are needed to clarify the causal relationship of Lp(a) and CVD in diabetic patients.",
keywords = "cardiovascular disease, diabetes, lipoprotein(a), Mendelian randomization, prospective studies",
author = "Qibin Qi and Lu Qi",
year = "2012",
month = "8",
doi = "10.2217/clp.12.46",
language = "English (US)",
volume = "7",
pages = "397--407",
journal = "Future Lipidology",
issn = "1758-4299",
publisher = "Future Medicine Ltd.",
number = "4",

}

TY - JOUR

T1 - Lipoprotein(a) and cardiovascular disease in diabetic patients

AU - Qi, Qibin

AU - Qi, Lu

PY - 2012/8

Y1 - 2012/8

N2 - Lipoprotein(a) (Lp[a]) is a LDL-like particle consisting of an ApoA moiety linked to one molecule of ApoB100. Recent data from large-scale prospective studies and genetic association studies provide highly suggestive evidence for a potentially causal role of Lp(a) in affecting risk of cardiovascular disease (CVD) in general populations. Patients with Type 2 diabetes display clustered metabolic abnormalities and elevated risk of CVD. Lower plasma Lp(a) levels were observed in diabetic patients in several recent studies. Epidemiology studies of Lp(a) and CVD risk in diabetic patients generated inconsistent results. We recently found that Lp(a)-related genetic markers did not predict CVD in two diabetic cohorts. The current data suggest that Lp(a) may differentially affect cardiovascular risk in diabetic patients and in the general population. More prospective studies, Mendelian randomization analysis and functional studies are needed to clarify the causal relationship of Lp(a) and CVD in diabetic patients.

AB - Lipoprotein(a) (Lp[a]) is a LDL-like particle consisting of an ApoA moiety linked to one molecule of ApoB100. Recent data from large-scale prospective studies and genetic association studies provide highly suggestive evidence for a potentially causal role of Lp(a) in affecting risk of cardiovascular disease (CVD) in general populations. Patients with Type 2 diabetes display clustered metabolic abnormalities and elevated risk of CVD. Lower plasma Lp(a) levels were observed in diabetic patients in several recent studies. Epidemiology studies of Lp(a) and CVD risk in diabetic patients generated inconsistent results. We recently found that Lp(a)-related genetic markers did not predict CVD in two diabetic cohorts. The current data suggest that Lp(a) may differentially affect cardiovascular risk in diabetic patients and in the general population. More prospective studies, Mendelian randomization analysis and functional studies are needed to clarify the causal relationship of Lp(a) and CVD in diabetic patients.

KW - cardiovascular disease

KW - diabetes

KW - lipoprotein(a)

KW - Mendelian randomization

KW - prospective studies

UR - http://www.scopus.com/inward/record.url?scp=84865836430&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865836430&partnerID=8YFLogxK

U2 - 10.2217/clp.12.46

DO - 10.2217/clp.12.46

M3 - Article

AN - SCOPUS:84865836430

VL - 7

SP - 397

EP - 407

JO - Future Lipidology

JF - Future Lipidology

SN - 1758-4299

IS - 4

ER -